COMPANY

Askgene Pharma

We are developing cytokine fusion molecules, especially antibody-cytokine prodrug fusion molecules, which selectively modulate a subset of immune cells in the tumor microenvironment. We are also developing cytokine fusion molecules for addressing autoimmune diseases and inflammation disorders. From company website Source · Oct 13, 2026

Keywords: molecules antibody Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Gastric Cancer Gastroesophageal Cancer ASKG315 ASKB589 ASKG915

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

Jan 25, 2024 Trial start Phase 3: ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma source ↗
Aug 9, 2023 Trial start 1: A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors source ↗
Aug 2, 2023 Trial start Phase 1/Phase 2: A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. source ↗
Feb 21, 2023 Trial start Phase 1/Phase 2: ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. source ↗
Oct 15, 2022 Trial start Phase 1: A Study of ASKG315 in Patients With Advanced Solid Tumors. source ↗

Upcoming milestones

Dec 30, 2026 (ESTIMATED) · Phase 3 · ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma · NCT06206733
Dec 31, 2026 (ESTIMATED) · Phase 1/Phase 2 · A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. · NCT05867420

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06206733	ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma	Phase 3	Active, not recruiting	Jan 25, 2024	Dec 30, 2026 (estimated)
NCT05867420	A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.	Phase 1/Phase 2	Recruiting	Aug 2, 2023	Dec 31, 2026 (estimated)
NCT05632939	ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.	Phase 1/Phase 2	Active, not recruiting	Feb 21, 2023	Oct 31, 2025 (estimated)
NCT05509985	A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors	1	Unknown status (ClinicalTrials.gov)	Aug 9, 2023	Sep 9, 2023 (estimated)
NCT05554666	A Study of ASKG315 in Patients With Advanced Solid Tumors.	Phase 1	Unknown status (ClinicalTrials.gov)	Oct 15, 2022	Dec 31, 2023 (estimated)